[Agranulocytosis induced by synthetic antithyroid drugs: efficacy of hematopoietic growth factors].

Abstract

Agranulocytosis is the most serious problem, potentially fatal, that can occur during antithyroid drug therapy. The use of hematopoietic growth factors is an attractive approach to reduce the period of this drug-induced neutropenia. We report two cases of severe antithyroid drug-related agranulocytosis (granulocyte count < 0.1 x 10(9)/L) treated with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). The delay to observe a granulocyte count superior to 1 x 10(9)/L was respectively 1 and 5 days. Our results, with others, clearly show that hematopoietic growth factors are effective in severe antithyroid drug-induced agranulocytosis.

• Authors: P Genet, M Pulik, F Lionnet, C Bremont
• Journal: Annales d'endocrinologie (Ann Endocrinol (Paris)) Vol. 55 Issue 1 Pg. 39-42 ( 1994) ISSN: 0003-4266 [Print] France
• Vernacular Title: Agranulocytose aux antithyroïdiens de synthèse: efficacité des facteurs de croissance hématopoïétique.
• PMID: 7528487 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antithyroid Agents
• Hormones
• Granulocyte Colony-Stimulating Factor
• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Adult
• Aged
• Aged, 80 and over
• Agranulocytosis (chemically induced, drug therapy)
• Antithyroid Agents (adverse effects)
• Female
• Granulocyte Colony-Stimulating Factor (therapeutic use)
• Granulocyte-Macrophage Colony-Stimulating Factor (therapeutic use)
• Hormones (adverse effects)
• Humans